-+ 0.00%
-+ 0.00%
-+ 0.00%

China NT Pharma FY26 H1 net loss narrows 2.18% to RMB 16.54 million; revenue more than doubles to RMB 23.67 million

PUBT·08/20/2026 14:21:34
Listen to the news
China NT Pharma FY26 H1 net loss narrows 2.18% to RMB 16.54 million; revenue more than doubles to RMB 23.67 million
  • China NT Pharma posted a net loss of RMB 16.54 million for the six months ended June 30, 2026, narrowing 2.18%.
  • Revenue more than doubled to RMB 23.67 million, up 97.3%.
  • Gross profit fell 30.6% to RMB 6.95 million as cost of services rose to RMB 16.72 million.
  • Finance costs eased 12% to RMB 12.84 million.
  • The group highlighted progress building a full-cycle bone-health platform, with phased commercialization and preliminary scale sales in related products.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China NT Pharma Group Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12293308), on August 20, 2026, and is solely responsible for the information contained therein.